🚀 May 12, Stocks on the U.S. Stock Exchange Soars More Than 100% 4🚀
1. DevvStream Corp. (DEVS)
290.93%
2. Kindly MD, Inc. (KDLY)
251.03%
3. Gryphon Digital Mining, Inc. (GRYP)
173.08%
4. CytomX Therapeutics, Inc. (CTMX)
129.43%
1. DevvStream Corp
📈 Company Overview
- Year of establishment: 2020
- Location: Vancouver, British Columbia, Canada
- Market cap: approximately $12 million (as of May 2025)
- Major projects: Management of carbon credits and environmental assets, development and investment of eco-friendly projects
- Specialized Areas: Blockchain-Based Carbon Credit Tracking System, Participation in Sustainable Energy Projects, ESG Asset Trading
- Latest Trends: Announcement Of 7 To 1 Stock Split, Increase Global Liquidity And Increase Access To Small Investors
- an official website : https://www.devvstream.com
The company is an acquisition target company. The company has merged, acquired assets, securities apps, reorganized, and it was established for a similar business combination.
We want to focus on the educational technology, enhanced production, financial technology, and health technology industries.
📈 the cause of a surge in stock prices
1. Market-wide gains following U.S.-China trade agreement
The U.S. and China struck a trade deal that sharply cuts mutual tariffs for 90 days, sending the overall U.S. stock market into positive territory. As a result, the Dow gained 2.8%, the S&P 500 gained 3.3%, and the Nasdaq gained 4.4%. It was especially strong, with tech and small and medium-sized stocks leading to buying in lower-priced growth stocks such as DEVS.
2. High Volatility and Technical Rebound
DEVS has been highly volatile in recent weeks, attracting short-term traders' attention. In particular, after hitting a low of $0.1752 on April 21, expectations of a technical rebound have created an influx of buying from investors.
3. Anticipation of entering the biogas market
DEVS announced in December 2024 that it was entering the biogas market through a partnership with Strategic Environmental & Energy Resources (SEER). This expansion of the business has attracted investors' attention, raising expectations for long-term growth potential.
# May 7, Cause for Stock Surge: 7 To 1 Stock Split Announced
- DevStream announced a stock split that splits one existing share into seven.
This led to a sharp inflow of investment buying as retail investor access increased and liquidity was expected to expand. .
📈 Listed information
|
an exchange
|
Nasdaq Stock Exchange
|
|
a current coin
|
USD
|
|
Settlement date
|
2024-12-31
|
|
Listed date
|
2021-12-20
|
|
Number of shares listed
|
30,115,734
|
|
market capitalization
|
$12,076,409
|
📈 Composition of shareholders
| Shareholder's name | Number of shares | specific gravity |
|
Devvio Inc
|
7,111,428
|
23.61%
|
|
Focus Impact Sponsor, LLC.
|
5,572,900
|
18.50%
|
|
Crestmont Investments LLC
|
2,000,000
|
6.64%
|
|
Helena Global Investment Opportunities I Ltd
|
1,441,560
|
4.79%
|
|
Polar Asset Management Partners Inc.
|
558,415
|
1.85%
|
2. Kindly MD Inc
📈 Company Overview
- Year of establishment: 2019
- Headquarters Location: Salt Lake City, Utah, USA
- Market cap (as of May 2025): approximately $23.5 million
- Key Business: KindlyMD is a patient-centered healthcare and medical data company that integrates prescription drugs and behavioral health services. It also combines traditional primary care, pain management, and alternative therapy to provide comprehensive medical services. It also directly operates four centers (including the largest non-narcotic pain treatment center) in Utah
- Specialized Area: KindlyMD provides the industry's first customized healthcare that combines traditional prescription drugs, behavioral health, and alternative medicine. It also highlights a data-driven strategy that builds its own patient database and utilizes it as a non-narcotic alternative medicine data source
- Latest Trends (as of May 2025): KindlyMD announced a merger with crypto investment company Nakamoto Holdings in May 2025 and is pursuing a bitcoin vault strategy. To that end, it raised a total of $710 million worth of investments in PIPE and convertible bonds, with KDLY shares jumping about 650 percent shortly after the merger was announced.
- Official website: kindlymd.com
The company is a healthcare data company focused on overall pain management and harm reduction in the opioid epidemic.
The company provides direct health care to patients by integrating prescription drugs and behavioral health services to reduce opioid use in the chronic pain patient population.
Professional outpatient clinical services are provided for a fee by service. It provides evaluation and management, including, but not limited to, chronic pain, functional medicine, cognitive behavioral therapy, trauma and addiction treatment, recovery support services, overdose educational activities, peer support, limited emergency treatment, preventive care, medical care, weight loss and hormone therapy.
It also collects data focusing on why and how patients seek alternative treatments to reduce prescription drug use and addiction.
All relevant data points are collected to assist and treat each patient appropriately.
📈 the cause of a surge in stock prices
1. Announcement of merger with holding company Nakamoto Holdings
The surge in KDLY's stock price was attributed to the company's announcement of a merger with its Bitcoin-focused holding company, Nakamoto Holdings.
Through the merger, KDLY plans to pursue its Bitcoin financial strategy, which it has secured $710 million in funding for.
The strategic move was met with a positive response from investors, leading to a rise in the stock price.
| category | content |
| the background of the surge |
Announcement of Merger With Nakamoto Holdings
|
|
Purpose of merger
|
Establishing Bitcoin (BTC)-based financial strategies and establishing Bitcoin Treasuries |
|
the scale of financing
|
$710 million in total ($510 million PIPE + $200 million convertible bonds)
|
|
post-merger strategy
|
Bitcoin holdings increase and Bitcoin yield per share (BTC Yield) expands
|
|
market reaction
|
Stocks Surge More Than 600 Percent, Volume Surges
|
|
leadership change
|
Nakamoto Holdings Founder David Bailey To Take Over As CEO After Merger |
📈 Listed information
|
an exchange
|
Nasdaq Stock Exchange
|
|
a current coin
|
USD
|
|
Settlement date
|
2024-12-31
|
|
Listed date
|
2024-05-31
|
|
Number of shares listed
|
6,022,148
|
|
market capitalization
|
$82,443,206
|
📈 Composition of shareholders
| Shareholder's name | Number of shares | specific gravity |
|
Wade Rivers LLC
|
2,886,744
|
47.94%
|
|
Townsquare Capital, LLC
|
701,000
|
11.64%
|
|
Sally Alicia LLC
|
350,000
|
5.81%
|
|
Gus Doodle LLC
|
350,000
|
5.81%
|
|
Cetera Investment Advisers LLC
|
230,794
|
3.83%
|
3. Gryphon Digital Mining Inc
📈 Company Overview
- Year of establishment: 2021
- Headquarters Location: Los Angeles, California, United States
- Market cap (as of May 2025): approximately $68 million
- Key Business: Gryphon Digital Mining is an eco-friendly bitcoin mining company that aims to operate "carbon neutral" mining that strictly complies with environmental, social, and governance (ESG) standards.
- Specialized area: It aims for 100% renewable energy-based bitcoin mining, and pursues mining efficiency and sustainability at the same time. It is maximizing operational efficiency through an 'asset-light' strategy that outsources mining equipment and data centers.
- Recent Trends (as of May 2025): In May 2025, Gryphon finalized its listing on Nasdaq and began trading. In particular, GRYP shares surged more than 60% on the first day of listing, along with a differentiated strategy of ESG-friendly Bitcoin mining. This, coupled with a rebound in Bitcoin prices and increased demand for ESG investment, attracted market attention.
- Official website: https://gryphondigitalmining.com
The company is (formerly Akerna Corp) Bitcoin mining company. The company focuses on bringing digital assets to the clean energy grid.
The company operates a task (block solving) to mine digital assets (called cryptocurrency) using a special computer (miner) equipped with an application-specific integrated circuit (ASIC) chip (miner) to solve complex cryptographic algorithms that support the Bitcoin blockchain and exchanges them for cryptocurrency rewards (mainly Bitcoin).
It operates by self-mining and ESG-led mining. It operates approximately 7,400 Bitcoin ASIC mining computers from Bitmain Technologies Limited installed in third-party hosted mining data centers located in New York, Georgia, and North Carolina.
It also focuses on improving digital asset network infrastructure. Bitcoin mining operations adopt a net carbon negative strategy.
📈 the cause of a surge in stock prices
1. announcement of merger
- Gryphon Digital Mining entered into a stock exchange-type merger agreement with American Bitcoin.
Upon completion of the merger, the new company will be listed on Nasdaq under the ticker "ABTC" under the name "American Bitcoin Corp."
2. equity structure
- Upon completion of the merger, existing American Bitcoin shareholders will own about 98% of the combined company,
Gryphon shareholders will hold about 2%.
3. Management composition
- The merged company will be led by American Bitcoin's board of directors and management.
American Bitcoin was co-founded by Hut 8 Corp. and Eric Trump in early 2025,
It aims to build Bitcoin mining infrastructure in the United States.
📈 Listed information
|
an exchange
|
Nasdaq Stock Exchange
|
|
a current coin
|
USD
|
|
Settlement date
|
2024-12-31
|
|
Listed date
|
2018-02-21
|
|
Number of shares listed
|
69,346,005
|
|
market capitalization
|
$98,471,327
|
📈 Composition of shareholders
| Shareholder's name | Number of shares | specific gravity |
|
Anchorage Lending CA LLC
|
8,287,984
|
11.95%
|
|
Tolhurst (Daniel George)
|
3,472,493
|
5.01%
|
|
Chang Advisory Inc.
|
3,309,648
|
4.77%
|
|
Roxy Capital Corp.
|
3,309,362
|
4.77%
|
|
RJL 18 Capital Canada LP
|
3,201,399
|
4.62%
|
4. CytomX Therapeutics Inc
📈 Company Overview
- Year of establishment: 2008
- Headquarters Location: South San Francisco, California, United States
- Market cap (as of May 2025): approximately $250 million
- Key Business: CytomX Therapeutics is a biotech specializing in the development of anti-cancer immunotherapy drugs, focusing on research to increase the accuracy of antibody treatments based on its own Probody platform.
- Specialized Area: Probody technology designs antibody treatments that are activated only in specific enzymatic environments around cancer cells, minimizing damage to normal cells and maximizing precision of targeted treatments.
- Recent Trends (as of May 2025): On May 10, 2025, CytomX announced that it had entered into a joint research and development agreement worth up to $880 million with U.S. pharmaceutical giant Moderna. CTMX shares have soared more than 75% in a single day since the announcement of the agreement, with the collaboration focused on co-developing next-generation immuno-cancer drugs.
- Official website: https://www.cytomx.com
The company is a clinical-stage oncology-focused biopharmaceutical company focused on developing new conditional activating biologic agents designed to be confined to tumor microenvironments.
The Company is using its Probody Therapy Technology platform to develop potential first-in-class and best-in-class antibody-based treatments.
The company's pipeline consists of therapeutic candidates across multiple treatment modulators, including antibody-drug conjugates (ADCs), T-cell conjugates, and cytokines.
Pipelines in the clinical stage include CX-904, CX-2051, and CX-801.
CX-904 is a conditionally activated T-cell binding antibody that targets epidermal growth factor receptors in tumor cells and CD3 receptors in T cells, and has a global co-development partnership with Amgen.
CX-2051 is a conditionally activated ADC that targets epithelial cell adhesion molecules (EpCAMs), with the potential for application to several EpCAM-expressing epithelial cancers.
📈 the cause of a surge in stock prices
1. Announces Positive Phase 1 Interim Results of CX-2051
CX-2051 is an antibody-drug conjugate (ADC) targeting EpCAM and has shown promising results in Phase 1 clinical trials in patients with late metastatic colorectal cancer.
Of the 18 patients treated in the 7.2, 8.6, and 10 mg/kg dose groups, 28% had a partial response, especially in the 10 mg/kg dose group, 3 of 7 (43%) had a partial response.
The disease control rate was 94%, and no significant adverse events or dose-limiting toxicity were observed.
2. Successful $100 Million Stock Offering
The company issued approximately 76.92 million shares at $1.30 per share, raising a total of $100 million in funding.
The funds will be used for CX-2051's clinical development and other R&D activities, which will ensure the Company's cash flow through the second quarter of 2026.
3. Q1 2025 Earnings Beat Expectations
In the first quarter of 2025, the company reported revenue of $50.92 million and net income per share of $0.27, which significantly beat estimates of $29.7 million and $0.06 per share, respectively.
4. Collaborate with Moderna and expand pipelines
Preclinical data on masked IL-12 molecules in co-development with Moderna have been published positively, suggesting potential expansion in the field of chemotherapy in the future.
📈 Listed information
|
an exchange
|
Nasdaq Stock Exchange
|
|
a current coin
|
USD
|
|
Settlement date
|
2024-12-31
|
|
Listed date
|
2015-10-08
|
|
Number of shares listed
|
80,621,293
|
|
market capitalization
|
$171,723,354
|
📈 Listed information
| Shareholder's name | Number of shares | specific gravity |
|
Tang Capital Management, LLC
|
7,311,760
|
9.07%
|
|
BVF Partners L.P.
|
5,228,461
|
6.49%
|
|
The Vanguard Group, Inc.
|
5,162,302
|
6.40%
|
|
Prosight Capital
|
3,905,000
|
4.84%
|
|
Millennium Management LLC
|
3,221,012
|
4.00%
|
📌 참조 : 5/6, 폭등한 NXTT, ABTS, NVVE 's chart soared today
